Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks

Eli Lilly to unveil major breast cancer data at SABCS 2025

Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years

FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures

Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels

Time Medical launches India’s first low-field TOF MRI for nationwide aneurysm screening

India presents one of the world’s largest untapped opportunities for neurovascular screening

New England Biolabs unveils high-speed flu sequencing tool to bolster global outbreak surveillance

Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing

Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

Johnson & Johnson gets FDA nod for new depression treatment

This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials

Amgen confident in US biosimilar market’s strength as sales surge 52%

Effective corrosion management demands a holistic approach: Experts

From material selection to cooling tower management, every small decision affects long-term equipment reliability